https://openbell.ai/ 2026-09-22T11:43:41.072Z hourly 1.0 https://openbell.ai/support 2026-09-22T11:43:41.072Z monthly 0.7 https://openbell.ai/privacy 2026-09-22T11:43:41.072Z monthly 0.5 https://openbell.ai/terms 2026-09-22T11:43:41.072Z monthly 0.5 https://openbell.ai/feed.json 2026-09-22T11:43:41.072Z hourly 0.8 https://openbell.ai/news/GRAB:1790077337046 2026-09-22T11:42:17.046Z daily 0.9 https://cdn.brandfetch.io/GRAB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Grab Stock Trading Higher Today? Grab Holdings (NASDAQ: GRAB) shares rose over 5% during premarket trading, following regulatory filings that revealed significant stock purchases by CEO Anthony Tan and President Alexander Hungate, totaling approximately $30.7 million. Tan acquired 10.35 million Class A shares at an average price of $2.8866, while Hungate purchased 299,571 shares at $2.8936. Additionally, Grab announced its acquisition of a 60% stake in Atome Financial for $1.49 billion, aiming to enhance its consumer lending business, with expectations of generating $500 million in adjusted EBITDA by 2028. https://openbell.ai/news/GRAB:1790077306141 2026-09-22T11:41:46.141Z daily 0.9 https://cdn.brandfetch.io/GRAB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Grab Stock Trading Higher Today? Grab Holdings (NASDAQ: GRAB) shares increased by over 5% in premarket trading following significant stock purchases by CEO Anthony Tan and President Alexander Hungate, totaling over $30.7 million. Tan acquired 10.35 million Class A shares at $2.8866 each, while Hungate purchased 299,571 shares at $2.8936. Additionally, Grab announced the acquisition of a 60% stake in Atome Financial for $1.49 billion, aiming to enhance its consumer lending business, with expectations of generating $500 million in adjusted EBITDA by 2028. https://openbell.ai/news/LLY:1790077116654 2026-09-22T11:38:36.654Z daily 0.9 https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week' Eli Lilly CEO Dave Ricks reported that the company has captured 70% of the 700,000 new seniors using GLP-1 treatments following Medicare's coverage expansion. The newly launched obesity pill, Foundayo, is being chosen by one-third of new oral GLP-1 patients, with usage growing weekly. Eli Lilly is also investing $6.5 billion in a new manufacturing site in Houston to produce Foundayo and plans to expand its international launch. Guggenheim analyst Seamus Fernandez raised his price target for Eli Lilly to $1,284, citing strong sales forecasts for Foundayo, projecting $1.8 billion in 2027 and $3.7 billion in 2028. https://openbell.ai/news/FSLY:1790077012581 2026-09-22T11:36:52.581Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Stuttgart--Germany---Aug-23--2021-Person.jpg?width=250&height=187 Fastly’s AI Security Push Adds Heat Ahead Of Investor Day Fastly, Inc. (NASDAQ: FSLY) shares rose nearly 15% on Monday, trading at $27.75 in premarket on Tuesday, ahead of its Investor Day where management will discuss revenue growth and product strategy. The company reported a 23% year-over-year increase in second-quarter revenue, with security revenue up 43%. Fastly has launched new AI security products, including AI Firewall and AI Runtime Control, as machine-generated traffic now constitutes over 50% of its network traffic. Analysts have set an average price target of $28.14 for the stock, with upcoming earnings expected to show an EPS of 8 cents on revenue of $187.59 million. https://openbell.ai/news/KZIA:1790076821409 2026-09-22T11:33:41.409Z daily 0.9 https://cdn.brandfetch.io/KZIA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies Kazia Therapeutics Limited (NASDAQ: KZIA) announced that Sovargen Co., Ltd. has dosed the first participant in a Phase 1b/2a clinical trial of paxalisib, aimed at treating intractable epilepsy associated with focal cortical dysplasia type 2 and tuberous sclerosis complex. This milestone triggers a $2 million development payment to Kazia under their licensing agreement with Sovargen. https://openbell.ai/news/CNSY:1790076781721 2026-09-22T11:33:01.721Z daily 0.9 https://cdn.brandfetch.io/CNSY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cerenome's CNSide Diagnostics Announces In-Network Agreement With Blue Cross Blue Shield Of Michigan, Covering About 5M Members, Effective September 1 openbell Financial News https://openbell.ai/news/GBX:1790076752126 2026-09-22T11:32:32.126Z daily 0.9 https://cdn.brandfetch.io/GBX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Greenbrier Receives ~$600M Orders For 3,400 New Railcars The Greenbrier Companies, Inc. (NYSE: GBX) announced it has received orders for 3,400 new railcars valued at approximately $600 million during its fiscal fourth quarter ending August 31, 2026. The orders include 780 railcars for the Saudi Arabian government-owned SAR and cover various railcar types and end markets. https://openbell.ai/news/BBNX:1790076730846 2026-09-22T11:32:10.846Z daily 0.9 https://cdn.brandfetch.io/BBNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Beta Bionics Announces Partnership To Integrate iLet Insulin Pump With Senseonics' Eversense 365 Glucose Monitor, Expects Q4 2026 Launch openbell Financial News https://openbell.ai/news/CLGN:1790076705068 2026-09-22T11:31:45.068Z daily 0.9 https://cdn.brandfetch.io/CLGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud CollPlant Biotechnologies Regains Nasdaq Compliance CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) has received formal notification from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share for its common stock. https://openbell.ai/news/VICR:1790076421916 2026-09-22T11:27:01.916Z daily 0.9 https://cdn.brandfetch.io/VICR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Vicor, Maintains $320 Price Target Needham analyst N. Quinn Bolton has reiterated a 'Buy' rating on Vicor (NASDAQ: VICR) and maintained a price target of $320 for the stock. This endorsement suggests confidence in Vicor's performance and potential for growth. https://openbell.ai/news/PSKY:1790076057762 2026-09-22T11:20:57.762Z daily 0.9 https://cdn.brandfetch.io/PSKY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Overweight on Paramount Skydance, Raises Price Target to $11.5 Morgan Stanley analyst Benjamin Swinburne has maintained an Overweight rating on Paramount Skydance (NASDAQ: PSKY) and raised the price target from $10 to $11.5. This adjustment reflects a positive outlook for the company's performance in the market. https://openbell.ai/news/VICR:1790075777172 2026-09-22T11:16:17.172Z daily 0.9 https://cdn.brandfetch.io/VICR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Market-Moving News for September 22nd Vicor (VICR) shares rose by 13% after the company raised its Q3 revenue guidance. Viking Therapeutics (VKTX) reported a 38% increase in shares following positive top-line results from a maintenance study of VK2735, showing a 22% placebo-adjusted weight loss at week 33. Quanome Technologies (QNME) saw an 80% increase in shares after entering a Purchase and Sale Agreement with Compal Electronics for 32 GPU server units. https://openbell.ai/news/ZBIO:1790075756582 2026-09-22T11:15:56.582Z daily 0.9 https://cdn.brandfetch.io/ZBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026 Zenas BioPharma, Inc. (NASDAQ: ZBIO) will present new data from its Phase 3 INDIGO trial evaluating obexelimab for immunoglobulin G4-related disease (IgG4-RD) at two upcoming scientific meetings: the 6th International Symposium on IgG4-Related Disease from October 8-10, 2026, and the American College of Rheumatology (ACR) Convergence 2026 from November 6-11, 2026. The presentations will include longer-term flare protection and safety data, as well as analyses on glucocorticoid-associated toxicity and vaccine responses in patients treated with obexelimab. https://openbell.ai/news/LGND:1790075618225 2026-09-22T11:13:38.225Z daily 0.9 https://cdn.brandfetch.io/LGND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ligand Pharmaceuticals Announces Acquisition Of EMEA Royalty On Santen's Pediatric Myopia Drug Ryjunea From Sydnexis For $23M Upfront openbell Financial News https://openbell.ai/news/EDBL:1790075522045 2026-09-22T11:12:02.045Z daily 0.9 https://cdn.brandfetch.io/EDBL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Edible Garden Awarded Fresh-Cut Herb Business Through Walmart Distribution Center Serving The Upper Midwest Edible Garden has been awarded the fresh-cut herb business through a Walmart distribution center serving the Upper Midwest, building on its recent expansion in the Mid-Atlantic region. The distribution center will be serviced by Edible Garden Heartland in Grand Rapids, Michigan, enhancing the company's distribution network. This move is expected to increase fresh-cut herb volume and improve operational efficiencies, while positioning Edible Garden for further growth with Walmart and other retailers. https://openbell.ai/news/RXST:1790075517395 2026-09-22T11:11:57.395Z daily 0.9 https://cdn.brandfetch.io/RXST/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5 B of A Securities analyst Craig Bijou has maintained an 'Underperform' rating on RxSight (NASDAQ: RXST) and reduced the price target from $6.5 to $5.5. https://openbell.ai/news/ELDN:1790075500578 2026-09-22T11:11:40.578Z daily 0.9 https://cdn.brandfetch.io/ELDN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society Eledon Pharmaceuticals presented updated long-term data from its Phase 2 BESTOW clinical program for tegoprubart at the International Congress of The Transplantation Society. The data showed that tegoprubart-treated patients had a statistically significant advantage in kidney function, with a mean eGFR of 71 mL/min/1.73 m² compared to 58 mL/min/1.73 m² for tacrolimus at 24 months. Additionally, no rejections occurred in the tegoprubart group beyond six months post-transplant, while seven rejections were reported in the tacrolimus group. Eledon has received FDA Fast Track designation for tegoprubart and plans to initiate a Phase 3 LEGACY study in Q4 2026, aiming to enroll approximately 600 patients. https://openbell.ai/news/PLUG:1790075486692 2026-09-22T11:11:26.692Z daily 0.9 https://cdn.brandfetch.io/PLUG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Plug Power Announces 1 MW GenEco Electrolyzer Shipment To HWR Hydrogen For New Zealand Refueling Station openbell Financial News https://openbell.ai/news/EWTX:1790075436837 2026-09-22T11:10:36.837Z daily 0.9 https://cdn.brandfetch.io/EWTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Edgewise Therapeutics Says Preclinical Data Show Hypertrophic Cardiomyopathy Candidate EDG-7500 Improves Cardiac Relaxation While Preserving Pumping Function openbell Financial News https://openbell.ai/news/ELDN:1790075401653 2026-09-22T11:10:01.653Z daily 0.9 https://cdn.brandfetch.io/ELDN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 Eledon Pharmaceuticals announced that the FDA has granted Fast Track designation to its drug tegoprubart for preventing rejection in kidney transplantation. In a Phase 2 study, patients treated with tegoprubart showed a statistically significant improvement in kidney function, with a mean eGFR of 71 mL/min/1.73 m² compared to 58 mL/min/1.73 m² for those on tacrolimus at 24 months. The company plans to initiate a Phase 3 LEGACY study in the fourth quarter of 2026. https://openbell.ai/news/TNXP:1790075375121 2026-09-22T11:09:35.121Z daily 0.9 https://cdn.brandfetch.io/TNXP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA Tonix Pharmaceuticals has announced a second major managed Medicare agreement for its fibromyalgia treatment, TONMYA, which is effective immediately and adds approximately 21 million Medicare lives, bringing total Medicare coverage to 32 million lives in the U.S. This agreement expands total commercial and government payer coverage for TONMYA to about 166 million lives. The company has activated 50 new sales representatives, increasing its sales force to 150, to enhance access and awareness for TONMYA among fibromyalgia patients. https://openbell.ai/news/VKTX:1790075276029 2026-09-22T11:07:56.029Z daily 0.9 https://cdn.brandfetch.io/VKTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed Viking Therapeutics reported top-line results from a maintenance study of VK2735, a dual agonist targeting GLP-1 and GIP receptors, showing a 22% placebo-adjusted weight loss at week 33 after weekly dosing of 17.5 mg. The study indicated that up to 97% of weight loss was maintained with every other week dosing and 90% with monthly dosing over three months. The treatment exhibited excellent tolerability, with gastrointestinal adverse event rates comparable to placebo. A conference call is scheduled for 8:00 a.m. ET today. https://openbell.ai/news/KKR:1790075200397 2026-09-22T11:06:40.397Z daily 0.9 https://cdn.brandfetch.io/KKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud KKR Announces $350M Commitment From Its Funds To Launch Equipment Finance Company Akrapoint openbell Financial News https://openbell.ai/news/MDWD:1790075189856 2026-09-22T11:06:29.856Z daily 0.9 https://cdn.brandfetch.io/MDWD/w/400/h/400?c=1idopYfmtR7ZKg8QMud MediWound Announces Additional $3.3M In Department Of War Funding To Develop Room-Temperature-Stable NexoBrid For Battlefield Burn Care openbell Financial News https://openbell.ai/news/GEHC:1790075147738 2026-09-22T11:05:47.738Z daily 0.9 https://cdn.brandfetch.io/GEHC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Initiates Coverage On GE HealthCare Techs with Buy Rating, Announces Price Target of $93 Needham analyst David Saxon has initiated coverage on GE HealthCare Technologies (NASDAQ: GEHC) with a Buy rating. The analyst has set a price target of $93 for the stock. https://openbell.ai/news/LXEO:1790075136218 2026-09-22T11:05:36.218Z daily 0.9 https://cdn.brandfetch.io/LXEO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lexeo Therapeutics Announces Deal To Acquire Mantle Therapeutics For $8.3M Upfront, Up To $13M In Milestones, Adding Friedreich Ataxia Programs openbell Financial News https://openbell.ai/news/CGNX:1790075128447 2026-09-22T11:05:28.447Z daily 0.9 https://cdn.brandfetch.io/CGNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cognex Agrees To Acquire RealSense For ~$500M Cognex Corporation has announced its agreement to acquire RealSense for approximately $500 million, funded entirely through existing cash and investments. This acquisition aims to enhance Cognex's presence in the rapidly growing robotic perception market, which is currently valued at $600 million and projected to grow over 25% annually to about $1.6 billion by 2030. RealSense is expected to generate revenue between $80 million and $90 million in 2026, reflecting over 50% growth from the previous year. The deal is anticipated to close in the fourth quarter of 2026, pending customary closing conditions. https://openbell.ai/news/CLDX:1790075106611 2026-09-22T11:05:06.611Z daily 0.9 https://cdn.brandfetch.io/CLDX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for Barzolvolimab, showing that both studies met primary and key secondary endpoints at 12 weeks. The treatment demonstrated significant efficacy in patients with chronic spontaneous urticaria (CSU), particularly those refractory to omalizumab and with severe disease. The therapy was well tolerated, and the company plans to continue treatment in both trials for up to 52 weeks, with a Biologics License Application (BLA) submission expected in 2027. https://openbell.ai/news/GOGO:1790075012565 2026-09-22T11:03:32.565Z daily 0.9 https://cdn.brandfetch.io/GOGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gogo’s Military/Government Division Gogo Special Missions And Insitu Complete Testing And Integration Of Modified High-Speed Satellite Connectivity Solution, Tailored Specifically For Group 3 UAS Gogo Special Missions, the military/government division of Gogo (NASDAQ: GOGO), has successfully completed testing and integration of a modified high-speed satellite connectivity solution designed for Group 3 Uncrewed Aerial Systems (UAS) in collaboration with Insitu, a Boeing company. This partnership aims to optimize the Gogo Galileo HDX antenna for use on Insitu’s Integrator UAS, enhancing connectivity capabilities for military applications. https://openbell.ai/news/IMSR:1790074907373 2026-09-22T11:01:47.373Z daily 0.9 https://cdn.brandfetch.io/IMSR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roth Capital Initiates Coverage On Terrestrial Energy with Buy Rating, Announces Price Target of $15 Roth Capital analyst Craig Irwin has initiated coverage on Terrestrial Energy (NASDAQ: IMSR) with a Buy rating. The firm has set a price target of $15 for the company's stock. https://openbell.ai/news/ACN:1790074873979 2026-09-22T11:01:13.979Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Warsaw--Poland---May-2020-Accenture-Comp.jpg?width=250&height=187 Accenture, Google Cloud Advance Automotive AI Software Development With Volvo Cars Accenture PLC (NYSE: ACN) and Google Cloud have named Volvo Cars as the lead industry partner for Horizon, an open-source platform aimed at accelerating the development of Android Automotive Operating System (AAOS) software. Volvo Cars is transitioning its global AAOS development to Horizon, which integrates cloud-native tools and AI-assisted workflows to enhance engineering productivity. Additionally, Accenture has partnered with Anthropic to invest at least $1 billion each over the next five years to improve AI safety. https://openbell.ai/news/JBL:1790074868044 2026-09-22T11:01:08.044Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Jabil-Sign-Logo--Jabil-Inc--Is-An-Americ.jpg?width=250&height=187 Top Wall Street Forecasters Revamp Jabil Expectations Ahead Of Q4 Earnings Jabil Inc. (NYSE: JBL) is set to report its fourth quarter earnings on September 30, with analysts predicting earnings of $4.07 per share, an increase from $3.29 per share in the previous year. The expected quarterly revenue is $9.7 billion, up from $8.25 billion last year. The company also announced a $1.5 billion buyback plan in July. Jabil's shares rose 1.4% to close at $303.67 on Monday. https://openbell.ai/news/CRCL:1790074755897 2026-09-22T10:59:15.897Z daily 0.9 https://cdn.brandfetch.io/CRCL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Circle Internet Announces $100M Sale Of 1,237,011 Shares To Binance At $80.84 Per Share; Companies Expand Strategic Partnership Relating To Promotion Of USDC Held Through Circle’s Modular Smart Contract Wallet Infrastructure Service On September 17, 2026, Circle Internet Group, Inc. announced a $100 million sale of 1,237,011 shares of its Class A common stock to Binance at a price of $80.84 per share. This transaction is part of an expanded strategic partnership with Binance to promote USDC through Circle's Modular Smart Contract Wallet infrastructure service. The partnership has a five-year term, with provisions for unilateral termination under specified conditions. https://openbell.ai/news/GOOGL:1790074749583 2026-09-22T10:59:09.583Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Microsoft-versus-Google.jpg?width=250&height=187 Big Tech’s AI Debt Spree Hits a Wall as Bond Investors Demand Higher Yields From Alphabet, Meta and Nvidia Alphabet Inc., Meta Platforms Inc., and Nvidia Corp. are experiencing higher borrowing costs as bond markets adjust to increased debt issuance for AI infrastructure. Alphabet's credit spreads widened by 15 basis points from 56 to 71 basis points as issuance sizes grew from $1.25 billion to $3.50 billion, while similar trends were observed for Meta and Nvidia with $4 billion bond offerings. Total funding required for AI infrastructure has reached $5.5 trillion, with only $1 trillion in organic cash flow and $400 billion in incremental equity available, forcing these companies to rely heavily on high-grade bond markets. https://openbell.ai/news/BFLY:1790074714571 2026-09-22T10:58:34.571Z daily 0.9 https://cdn.brandfetch.io/BFLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Initiates Coverage On Butterfly Network with Buy Rating, Announces Price Target of $10 Needham analyst David Saxon has initiated coverage on Butterfly Network (NYSE: BFLY) with a Buy rating. The firm has set a price target of $10 for the company's stock. https://openbell.ai/news/MRK:1790074110830 2026-09-22T10:48:30.830Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial Merck (NYSE: MRK) announced that the FDA has approved an update to the product label for WINREVAIR (sotatercept-csrk) for injection, based on results from the Phase 3 HYPERION trial. The trial demonstrated that adding WINREVAIR to background therapy reduced the risk of clinical worsening events by 76% in adults with pulmonary arterial hypertension (PAH) compared to placebo. The updated label now includes efficacy and safety data for adults diagnosed with PAH within the last 12 months, highlighting the drug's role in early treatment. https://openbell.ai/news/KYMR:1790073830786 2026-09-22T10:43:50.786Z daily 0.9 https://cdn.brandfetch.io/KYMR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152 Stifel analyst Alex Thompson has maintained a Buy rating on Kymera Therapeutics (NASDAQ: KYMR) and increased the price target from $132 to $152. https://openbell.ai/news/OMER:1790073587102 2026-09-22T10:39:47.102Z daily 0.9 https://cdn.brandfetch.io/OMER/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Upgrades Omeros to Overweight, Announces $22 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders has upgraded Omeros (NASDAQ: OMER) from a Neutral to an Overweight rating. The firm has set a price target of $22 for the stock. https://openbell.ai/news/ENTX:1790073377873 2026-09-22T10:36:17.873Z daily 0.9 https://cdn.brandfetch.io/ENTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating Cantor Fitzgerald analyst Imogen Mansfield has initiated coverage on Entera Bio (NASDAQ: ENTX) with an Overweight rating. This marks a significant endorsement for the company as it seeks to attract investor interest. https://openbell.ai/news/WST:1790073367368 2026-09-22T10:36:07.368Z daily 0.9 https://cdn.brandfetch.io/WST/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400 Morgan Stanley analyst Kallum Titchmarsh has upgraded West Pharmaceutical Services (NYSE: WST) from Equal-Weight to Overweight. The price target for the stock has been raised from $365 to $400. https://openbell.ai/news/VGZ:1790073137995 2026-09-22T10:32:17.995Z daily 0.9 https://cdn.brandfetch.io/VGZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Vista Gold, Maintains $4.5 Price Target HC Wainwright & Co. analyst Heiko F. Ihle has reiterated a Buy rating on Vista Gold (AMEX: VGZ) and maintained a price target of $4.5. This endorsement reflects the firm's confidence in the company's performance and outlook. https://openbell.ai/news/GOOG:1790073075079 2026-09-22T10:31:15.079Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Disappointed-stressed-woman-and-AI-robot.jpg?width=250&height=187 Economist Justin Wolfers Warns AI Could Leave Workers Earning ‘Two Pennies an Hour’ While OpenAI Gets ‘Infinitely Rich’ Economist Justin Wolfers warned that AI could lead to a significant reduction in job availability, with workers potentially earning as little as 'two pennies an hour' while companies like OpenAI become extremely wealthy. He emphasized the need for universal basic income as a necessary societal payment, rather than a form of redistribution. Additionally, a report indicated that advertised pay in the most AI-exposed occupations has surged by 46% since 2021, highlighting a widening pay gap between AI-exposed and less exposed jobs. https://openbell.ai/news/TVTX:1790072989949 2026-09-22T10:29:49.949Z daily 0.9 https://cdn.brandfetch.io/TVTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Travere Therapeutics (NASDAQ: TVTX) and maintained a price target of $67 for the stock. This reaffirms the firm's positive outlook on the company's performance. https://openbell.ai/news/EGO:1790072737637 2026-09-22T10:25:37.637Z daily 0.9 https://cdn.brandfetch.io/EGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Upgrades Eldorado Gold to Buy, Raises Price Target to $54 B of A Securities has upgraded Eldorado Gold (NYSE: EGO) from Underperform to Buy, with the price target increased from $32 to $54. This upgrade reflects a positive outlook on the company's performance. https://openbell.ai/news/BLK:1790072623070 2026-09-22T10:23:43.070Z daily 0.9 https://cdn.brandfetch.io/BLK/w/400/h/400?c=1idopYfmtR7ZKg8QMud BlackRock Signs MoU With Uzbekistan Central Bank To Explore Future Opportunities For Cooperation BlackRock has signed a Memorandum of Understanding (MoU) with the Central Bank of Uzbekistan to explore future cooperation opportunities. This strategic partnership aims to enhance financial collaboration and investment in Uzbekistan's markets. The specific terms and potential financial implications of the agreement were not disclosed. https://openbell.ai/news/ALP:1790072542185 2026-09-22T10:22:22.185Z daily 0.9 https://cdn.brandfetch.io/ALP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Alpha Compute Executes Definitive Real Estate And Operating Oil and Gas Asset Purchase Agreements in Pennsylvania Alpha Compute has executed definitive purchase agreements for over 300 acres of surface, mineral, and gas rights in Pennsylvania for $5.5 million, including over 75 existing oil and gas wells. The acquisition is expected to enhance the company's next-generation compute infrastructure while adhering to local regulations and promoting environmental stewardship. Preliminary evaluations indicate that the existing operations are generating revenue, with an estimated 4% of the surface oil extracted to date, making the site financially self-sustaining. The project aims to create jobs, modernize infrastructure, and align with local development goals. https://openbell.ai/news/AMZN:1790072493820 2026-09-22T10:21:33.820Z daily 0.9 https://cdn.brandfetch.io/AMZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud AWS Partners With The Biological Computing Co. To Bring World’s First Neuron-Derived AI Video Model To Market Amazon Web Services (AWS) has announced a partnership with The Biological Computing Company to launch the world's first neuron-derived AI video model. This innovative technology aims to enhance video processing capabilities by mimicking biological neural networks. The collaboration is expected to position AWS at the forefront of AI advancements in video technology, potentially impacting its market share in the AI sector. https://openbell.ai/news/HYPR:1790072235962 2026-09-22T10:17:15.962Z daily 0.9 https://cdn.brandfetch.io/HYPR/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target BTIG analyst Marie Thibault has reiterated a Buy rating on Hyperfine (NASDAQ: HYPR) and maintained a price target of $2 for the stock. This recommendation reflects confidence in the company's performance and potential growth. https://openbell.ai/news/CSX:1790072225920 2026-09-22T10:17:05.920Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Industrial-automation.jpg?width=250&height=187 Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q3 The article highlights three oversold stocks in the industrials sector that may present buying opportunities. Union Pacific Corp (NYSE: UNP) has an RSI of 19.4 and recently saw a price target increase from $310 to $339 despite a 13% stock decline, closing at $269.63. CSX Corp (NASDAQ: CSX) has an RSI of 21.9 with a reduced price target from $56 to $55, closing at $45.99 after an 11% drop. Waste Management Inc (NYSE: WM) holds an RSI of 25.1 and closed at $207.04 following a 9% decline, with analysts maintaining a Peer Perform rating. https://openbell.ai/news/PLXS:1790072129157 2026-09-22T10:15:29.157Z daily 0.9 https://cdn.brandfetch.io/PLXS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Upgrades Plexus to Overweight, Announces $300 Price Target Keybanc analyst Steve Barger has upgraded Plexus (NASDAQ: PLXS) from Sector Weight to Overweight, setting a price target of $300 for the stock. This upgrade indicates a positive outlook on Plexus's performance in the market.